共病
医学
不育
不明原因不孕症
内科学
前瞻性队列研究
队列
队列研究
男性不育
腰围
代谢综合征
女性不育
生殖医学
妇科
流行病学
风险因素
生殖健康
人口学
风险评估
生育率
产科
疾病严重程度
体质指数
糖尿病
作者
Edoardo Pozzi,Fausto Negri,M Raffo,L Boeri,Eugenio Ventimiglia,A d'Arma,Giada Amodio,Luca Pagliardini,Massimo Alfano,F Montorsi,Silvia Gregori,Andrea Salonia
摘要
INTRODUCTION: Male infertility is increasingly recognized as a systemic condition associated with impaired long-term health, yet clinically applicable frameworks linking reproductive dysfunction to comorbidity burden remain limited. Here, we investigated whether a composite immuno-metabolic signature could capture comorbidity burden and reduced reproductive capacity in men with primary male factor infertility (MFI). METHODS AND MATERIALS: In a cross-sectional cohort of 2953 men, metabolic and inflammatory variables were systematically screened for directional and independent associations with comorbidity burden, defined by the Charlson Comorbidity Index (CCI) ≥1, and impaired reproductive capacity, assessed by total motile sperm count (TMSC) <5 million. Three variables-LDL cholesterol, waist circumference, and C-reactive protein (CRP)-met selection criteria and were integrated into an unweighted standardized score. RESULTS: Three variables met selection criteria: LDL cholesterol, waist circumference, and C-reactive protein. Higher immuno-metabolic scores were observed in men with comorbidity burden (0.20 ± 0.73 vs. -0.02 ± 0.62, p < 0.001) and in those with TMSC <5M (0.13 ± 0.64 vs. -0.07 ± 0.62, p < 0.001). Each unit increase in the score was independently associated with comorbidity burden (OR 1.50, 95% CI 1.23-1.82, p < 0.001) and TMSC <5M (OR 1.67, 95% CI 1.48-1.89, p < 0.001). Predicted probabilities rose across the score range from 2% to 40% for comorbidity and from 12% to 75% for reduced reproductive capacity. CONCLUSION: These findings identify a biologically coherent immuno-metabolic signature linking spermatogenic impairment with systemic comorbidity in men with primary MFI and support a model in which male infertility reflects broader immuno-metabolic vulnerability. Prospective external validation is warranted before clinical implementation.
科研通智能强力驱动
Strongly Powered by AbleSci AI